Targeted therapy is estimated at 38.0% by treatment type in 2026 with intrahepatic cholangiocarcinoma at 46.0% and hospitals at 41.0% of end-user demand. Timely molecular profiling supports treatment selection as late diagnosis and narrow alteration groups restrict eligibility across specialist care pathways.
Cholangiocarcinoma Market Analysis By ApplicationCholangiocarcinoma Market Analysis By Distribution ChannelCholangiocarcinoma Market Analysis By Drug ClassCholangiocarcinoma Market Analysis By End UserCholangiocarcinoma Market Breakdown By Treatment Type, Application, And RegionCholangiocarcinoma Market Opportunity Matrix Growth Vs Value